Ashland Inc (ASH)

Nov 10, 2026

Ashland Inc. (NYSE: ASH) anticipates an earnings recovery in fiscal 2027 following a decline in 2026, driven by improved manufacturing productivity and strong demand for pharmaceutical and personal care ingredients. The company forecasts fiscal 2027 sales between $1.905 billion and $1.975 billion, with adjusted EBITDA ranging from $405 million to $435 million. This outlook comes after fiscal 2026 revenue increased 2% to $1.863 billion, but adjusted EBITDA fell 4% to $385 million.

Nov 4, 2026

Ashland Inc. reported strong fiscal 2026 with a 4% sales increase and a 2% rise in adjusted EBITDA, driven by growth in Life Sciences, Personal Care, and Specialty Additives. The company's strategic focus on "Globalize and Innovate" strategies led to significant sales growth and margin expansion in high-margin segments, despite raw material volatility and operational challenges at their Hopewell site. For fiscal 2027, Ashland projects sales between $1.905 billion and $1.975 billion and adjusted EBITDA from $405 million to $435 million, emphasizing sustained growth, improved manufacturing performance, and innovation as a long-term driver.

Nov 2, 2026

Ashland Inc. (NYSE: ASH) is scheduled to release its fourth-quarter and fiscal 2026 financial results on November 3, 2026, at approximately 5 p.m. Eastern Time. This will be followed by a presentation to securities analysts on November 4 at 9 a.m., featuring key executives including Chairman and CEO Guillermo Novo and CFO William Whitaker. The company will provide detailed management remarks and supporting materials on its investor relations website.